Peptides targeting the BTLA-HVEM complex can modulate T cell immune response

Eur J Pharm Sci. 2023 Dec 19:106677. doi: 10.1016/j.ejps.2023.106677. Online ahead of print.ABSTRACTImmune checkpoints secure the proper function of the immune system and the maintenance of the BTLA-HVEM complex, an inhibitory immune checkpoint, is one of the pathways vital for T cell responsiveness to various stimuli. The present study reports the immunomodulatory potential of five peptides targeting the BTLA-HVEM complex on the activity of human T cells. Isolated T cells were exposed to the peptides alone or combined with CD3/CD28 mAb for 72h or 120h. The flow cytometry was used to evaluate the activation markers (CD69, CD62L, CD25), changes within the T-cell memory compartment, proliferation rate, and apoptosis of T cells. The immunomodulatory effect of the peptides was visible as an increase in the percentage of CD4+ and CD8+ T cells expressing CD69 or CD25, a boost in T-cell proliferation, and shifts in the T-cell memory compartment. Pep(2) and Pep(5) were the most promising compounds, displaying a putative immune-restoring function.PMID:38128840 | DOI:10.1016/j.ejps.2023.106677
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Source Type: research